Analysis of p53, p16(MTS1), p21(WAF1) and H-ras in archived bladder tumours from workers exposed to aromatic amines

British Journal of Cancer

Volumn 77, Issue 10, 1998, Pages 1573-1579

  Sorlie T ^a   Martel Planche, G ^b   Hainaut, P ^b   Lewalter, J ^c   Holm, R ^a   Borresen Dale A L ^a   Montesano, R ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c BAYER AG   (Germany)

Author keywords

Aromatic amines; Bladder cancer; H ras mutations; p16(MTS1); p21(WAF1); p53

Indexed keywords

AROMATIC AMINE; CARCINOGEN; PROTEIN P16; PROTEIN P21; PROTEIN P53; AMINE; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; PROTEIN P16INK4A;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER GRADING; CLINICAL ARTICLE; CONTROLLED STUDY; EXON; HUMAN; HUMAN TISSUE; MALE; MUTATION RATE; OCCUPATIONAL EXPOSURE; ONCOGENE H RAS; POINT MUTATION; PRIORITY JOURNAL; TOBACCO; ADOLESCENT; BLADDER TUMOR; CHEMICALLY INDUCED DISORDER; GENETICS; MIDDLE AGED; OCCUPATIONAL DISEASE; ONCOGENE RAS; SMOKING; TRANSITIONAL CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; AMINES; CARCINOGENS; CARCINOMA, TRANSITIONAL CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; GENES, P53; GENES, RAS; HUMANS; MALE; MIDDLE AGED; OCCUPATIONAL DISEASES; POINT MUTATION; SMOKING; URINARY BLADDER NEOPLASMS;

EID: 0031961354     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.259     Document Type: Article

References (50)

1. Balazs M, Carroll P, Kerschmann R, Sauter G and Waldman FM (1997) Frequent homozygous deletion of cyclin-dependent kinase inhibitor 2 (MTS1.p16) in superficial bladder cancer delected by fluorescence in situ hybrization. Genes Chromosomes Cancer 19: 84-89
2. Borresen AL (1996) Constant denaturant gel electrophoresis (CDGE) in mutation screening. In Technology for Detection of DNA Damage and Mutation, Chapter 20. Pfeifer GP, (ed.), pp. 267-379 Plenum Press: New York
3. Boyko RW, Cartwright RA and Glashan RW (1985) Bladder cancer in dye manufacturing workers, J Occup Med 17: 799-803
4. Denissenko MF, Pao A, Tang MS and Pfeiffer GP (1996) Preferential formation of benzo(a)pyrene adducts at lung cancer mutational hotspots in p53. Science 274: 430-432
5. Essigmann JM and Wood ML (1993) The relationship between the chemical structures and mutagenic specificities of the DNA lesions formed by chemical and physical mutagens. Toxicol Lett 67: 29-39
6. Esteve A, Lehman T, Jiang W, Weinstein B, Harris CC, Ruol A, Peracchia A, Montesano R and Hollstein M (1993) Correlation of p53 mutations with epidermal growth factor receptor overexpression and absence of mdm2 amplification in human esophageal careinomas. Mol Carcinogenesis 8: 306-311
7. Esteve A, Sorlie T, Martel-Planche G, Hollstein M, Kusters I, Lewalter J, Vineis P, Stephan-Odenthal M and Montesano R (1995) Screening for p53 gene mutations in archived tumors of workers occupationally exposed to carcinogens: examples from analysis of bladder tumors. J Occup Environ Med 37: 59-68
8. Esleve A, Martel-Planche G, Sylla B, Hollstein M, Hainaut P and Montesano R (1996) Low frequency of p16/CDKN2 gene mutations in esophageal carcinomas. Int J Cancer 66: 301-304
9. Gonzalez-Zulueta M, Ruppert M, Tokino K, Tsai YC, Spruck III, CA, Miyao N, Nichols PW, Hermann GG, Horn T, Steven K, Summerhayes IC, Sidransky D and Jones PA (1993) Microsatellite instability in bladder cancer. Cancer Res 53: 5620-5623
10. Greenblatt MS, Bennett WP, Hollstein M and Harris CC (1994) Mutations in the p53 tumor suppressor gene: elues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878
11. Grossman HB, Liebert M, Lee IW and Lee SW (1994) Decreased connexin expression and intercellular communication in human bladder cancer cells. Cancer 54: 3062-3065
12. Habuchi T, Takahashi R, Yamada H, Ogawa O, Kakehi Y, Ogura K, Hamazaki S, Toguchida J, Ishizaki K, Fujita J, Sugiyama T and Yoshida O (1993) Influence of cigarette smoking and schistosomiasis on p53 gene mutation in urothelial cancer. Cancer Res 53: 3795-3799
13. Hainaut P, Soussi T, Shomer B, Hollstein M, Greenblait M, Hovig E, Harris CC and Montesano R (1997) Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucleic Acids Res 25: 151-157
14. Hsu SM, Raine L and Fanger H (1981) The use of antiavidin antibody and avidin-biotin peroxidase complex in immunoperoxidase technics. Am J Clin Pathol 75: 816-821
15. IARC (1972) Some Inorganic Substances, Chlorinated Hydrocarbons, Aromatic Amines, N-nitroso Compounds, and Natural Products, Vol. 1, International Agency for Research on Cancer: Lyon
16. IARC (1987) Silica and Some Silicates. Vol. 42. International Agency for Research on Cancer: Lyon
17. IARC (1994) Schistosomes, Liver Flukes Helicobacter pylori. Vol. 61. International Agency for Research on Cancer: Lyon
18. Jones PA, Buckley JD, Henderson BE, Ross RK and Pike MC (1991) From gene to carcinogen: a rapidly evolving field in molecular epidemiology. Cancer Res 51: 3617-3720
19. Kai M, Arakawa H, Sugimoto Y, Murata Y, Ogawa M and Nakamura Y (1995) Infrequent somatic mutation of the MTS1 gene in primary bladder carcinomas. Jpn J Cancer Res 86: 249-251
20. Kelley MJ, Oiterson GA, Kaye FJ, Popescu NC, Johnson BE and Dipaolo JA (1995) CDKN2 in HPV-positive and HPV-negative cervical-carcinoma cell lines. Int J Cancer 63: 226-230
21. Knowles MA and Williamson M (1993) Mutation of H-ras is infrequent in bladder cancer: conformation by single-strand conformation polymorphism analysis, designed restriction fragment length polymorphisms and direct sequencing. Cancer Res 53: 133-139
22. Knowles MA, Elder PA, Williamson M, Cairns JP, Shaw ME and Law MG (1994) Allelotype of human bladder cancer. Cancer Rev 54: 531-538
23. La Vecchia C, Negri E, D'avanzo B and Franceschi S (1990) Occupation and the risk of bladder cancer. Int J Epidemiol 19: 264-268
24. Lasco DD, Harvey SS, Maliakal SB, Kadlubar FF and Essigmann JM (1988) Specificity of mutagenesis by 4-aminobiphenyl. J Biol Chem 263: 15429-15435
25. Lehman TA, Bennett WP, Metcalf RA, Welsh JA, Ecker J, Modali RV, Ullrich S, Romano JW, Appclla E, Testa JR, Gerwin BI and Harris CC (1991) p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res 51(15): 4090-4096
26. Lehman TA, Modali R, Boukamp P, Stanek J, Bennett WP, Welsh JA, Metcalf RA, Stampfer MR, Fuscnig N, Rogan EM and Harris CC (1993) p53 mutations in human immortalized epithelial cell lines. Cracinogenesis 14: 833-839
27. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88: 323-331
28. Lianes P, Orlow I, Zhang ZF, Oliva MR, Sarkis AS, Reuter VE and Cordon-Cardo C (1994) Altered patterns of MDM2 and TP53 expression in human bladder cancer. J Natl Cancer Inst 86: 1325-1330
29. Miyamoto H, Shuin T, Torigoe S, Iwasaki Y and Kubota Y (1995) Retinoblastoma gene mutations in primary human bladder cancer. Br J Cancer 71: 831-835.
30. Nguyen, M, Watanabe, H, Budson AE, Richie JP and Folkman J (1993) Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients, J Nutl Cancer Inst 85: 241-242
31. Okajima E, Fukuda T, Okita S, Tsutsumi M, Hirao, Y, Okajima E and Konishi Y (1996) Infrequent somatic alteration of p16/MTS1 in human primary superficial bladder cancers. Cancer Lett 103: 227-231
32. Packenham JP, Taylor JA, Anna CH, White CM and Devereux TR (1995) Homozygous deletions but no sequence mutations in coding regions of p15 or p16 in human primary bladder tumors. Mol Carcinog 14: 147-151
33. Parkin, DM, Pisani P and Ferluy J (1993) Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 54: 594-606
34. Pisani P, Parkin DM and Ferlay J (1993) Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer 55: 891-903
35. Reznikoff CA, Kao C, Messing EM, Newton M and Swaminathan S (1993) A molecular genetic model of human bladder carcinogenesis. Cancer Biol 4: 143-152
36. Sauter G, Moch H, Moore, D, Carroll P, Kerschmann R, Chew K, Mihatsch MJ, Gudal F and Waldman F (1993) Heterogeneity of erhB-2 gene amplification in bladder cancer. Cancer Res 53: 2199-2203
37. Sheikh MS, Li XS, Chen JC, Shao ZM, Ordonez JV and Fontana JA (1994) Mechanisms of regulation of WAF1/Cip1 gene expression in human breast carcinoma: role of p53-dependent and independent signal transduction pathways. Oncogene 9: 3407-3415
38. Shihata A, Ohneseit PF, Tsai YC, Spruck CH 3rd, Nichols PW, Chiang HS, Lai MK and Jones PA (1994) Mutational spectrum in the p53 gene in bladder tumors from the endemic area of black foot disease in Taiwan. Carcinogenesis 15: 1085-1087
39. 1NK4A): somatic and germline mutations. Human Mutat 7: 294-303
40. Southgate J, Proffitt J, Roberts P, Smith B and Selby P (1995) Loss of cyclin-dependent kinase inhibitor genes and chromosome 9 karyotypic abnormalities in human bladder cancer cell lines. Br J Cancer 72: 1214-1218
41. Spruck CH, Rideout WM, Olumi AF, Ohneseit PF, Yang AS, Tsai, YC, Nichols, PW, Horn T, Hermann GG, Steven K, Ross RK, Yu MC and Jones PA (1993) Distinct pattern of p53 mutations in bladder cancer: relationship to tobacco usage. Cancer Res 53: 1162-1166
42. Studler WM and Olopade OI (1996) The 9p21 region in bladder cancer cell lines: large homozygous deletions inactivate the CDKN2, CDKN2B and MTAP genes. Urol Res 24: 239-244
43. 32P-postlabelling and subsequent thin-layer and high-pressure liquid chromatography. Carcinogenesis 11: 639-646
44. Taylor JA, Li Y, He M, Mason T, Mettlin C, Vogler WJ, Maygurde S and Liu E (1996) p53 mutations in bladder tumors from arylamine-exposed workers, Cancer Res 56: 294-298
45. Vet JA, Bringuier PP, Poddighe PJ, Karthaus HF, Debruyne FM and Schalken JA (1994) p53 mutations have no additional prognostic value over stage in bladder cancer. Br J Cancer 70: 496-500
46. Vineis P, Talaska G, Malaveille C, Bartsch H, Martone T, Sithisarankul P and Strickland P (1996) DNA adducts in urothelial cells: relationship with biomarkers of exposure to arylamines und polycyclic aromatic hydrocarbons from tobacco smoke. Int J Cancer 65: 314-316
47. Williamson MP, Elder PA and Knowles MA (1994) The spectrum of TP53 mutations in bladder carcinoma, Genes Chromosomes Cancer 9: 108-118
48. Williamson MP, Elder PA, Shaw ME, Devlin J and Knowles MA (1995) p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer. Hum Mol Genet 4: 1569-1577
49. Zhang W, Grasso L, McClain CD, Gambel AM, Cha Y, Travali S, Deisseroth AB and Merc E (1995) p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation. Cancer Res 55: 668-674
50. Zhang H, Chen ZH and Savarese TM (1996) Codeletion of the genes for p16INK4, methylthioadenosine phosphorylase, interferon-alpha 1, interferon-betal, and other 9p21 markers in human malignant cell lines. Cancer Genet Cytogenet 86: 22-28